Drug Trial Radar · NCT00789555
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Feb 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,260
Actual
Start
Nov 2008
Primary completion
Jan 2011
Study completion Jan 2011
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).
Conditions
- Perennial Allergic Rhinitis
Interventions
Olopatadine hydrochloride 0.6% nasal spray (PATANASE)Drug
Two sprays in each nostril twice a day (morning and evening) for up to 12 months
Olopatadine nasal spray vehicle, pH 3.7Other
Two sprays in each nostril twice a day (morning and evening) for up to 12 months
Olopatadine nasal spray vehicle, pH 7.0Other
Two sprays in each nostril twice a day (morning and evening) for up to 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Nasal Examination Parameters to Exit (Month 12 or Sooner)Time frame: Baseline (Day 0), Exit (Month 12 or sooner)
- Self-Rated Relief Assessment at Day 30Time frame: Day 30
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon Call Center For Trial Locations
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.